{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:10:44Z","timestamp":1790802644246,"version":"4.1.0"},"reference-count":21,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Purif"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Optimal dialysate calcium concentration (DCa) has not been determined under less hypercalcemic vitamin D analogues and Ca-free phosphate (P) binders. &lt;i&gt;Methods:&lt;\/i&gt; Twelve hyperparathyroidic hemodialysis patients under sevelamer hydrochloride were treated with paricalcitol in three periods (A, B and C) under DCa of 3.5, 3 and 2.5 mEq\/l, respectively, in a 3-way open-label randomized crossover study. &lt;i&gt;Results:&lt;\/i&gt; Serum parathyroid hormone decreased in all periods. Under DCa = 2.5 mEq\/l, there was a need for longer treatment duration, higher paricalcitol doses and increased sevelamer doses for higher serum P levels. No differences in serum Ca were observed. Ca \u00d7 P values followed P changes. Episodes of Ca \u00d7 P &gt;55 mg&lt;sup&gt;2&lt;\/sup&gt;\/dl&lt;sup&gt;2&lt;\/sup&gt; were more frequent in the C period. &lt;i&gt;Conclusions:&lt;\/i&gt; Under paricalcitol and sevelamer, serum parathyroid hormone decreased without Ca increase under any DCa. DCa of 2.5 mEq\/l resulted in higher paricalcitol doses, increased serum P levels and more frequent high Ca \u00d7 P episodes and may not be optimal with the new medications.<\/jats:p>","DOI":"10.1159\/000190785","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T08:46:53Z","timestamp":1231922813000},"page":"182-186","source":"Crossref","is-referenced-by-count":5,"title":["Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients on Sevelamer Hydrochloride: Which Dialysate Calcium Concentration to Use?"],"prefix":"10.1159","volume":"27","author":[{"given":"Macroui","family":"Sonikian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Metaxaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karatzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimosthenis","family":"Vlassopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038%2Fncpneph0189"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.2003.00878.x"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053%2Fajkd.2001.28112"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053%2Fajkd.1998.v32.pm9808143"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfh102"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053%2Fajkd.1998.v32.pm9669433"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI106529"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI106530"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.2000.00062.x"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1081%2FJDI-200048238"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2F18.3.582"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080%2F08860220600599092"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa022536"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053%2Fajkd.1998.v32.pm9808145"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038%2Fki.1989.277"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1774-9987.2005.00216.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1774-9987.2005.00210.x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2F13.suppl_3.62"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159%2F000188934"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1525-139X.1990.tb00001.x"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016%2F0002-9343%2874%2990811-0"}],"container-title":["Blood Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/190785","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/190785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:14:37Z","timestamp":1745450077000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000190785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000190785","archive":["Portico"],"relation":{},"ISSN":["0253-5068","1421-9735"],"issn-type":[{"value":"0253-5068","type":"print"},{"value":"1421-9735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}